The article discusses the potential cybersecurity risks associated with mergers and acquisitions (M&A) in the healthcare sector. It highlights the need for organizations to implement stringent security checks and due diligence to mitigate possible threats and ensure data protection. The report implies a strong “buyer beware” warning for these dealmakers.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
